Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cyclic AMP-responsive element-binding protein 3-like protein 3 is a transcription factor of the basic leucine zipper family predominantly localized to the endoplasmic reticulum membrane. Upon ER stress or cyclic AMP stimulation, it undergoes regulated proteolysis, releasing an active fragment that translocates to the nucleus to control gene expression related to lipid and glucose metabolism, iron homeostasis, acute inflammatory response, and hepatic circadian regulation. It acts in concert with nuclear receptors and coactivators (such as PPARα) to promote fatty acid oxidation, ketogenesis, and expression of FGF21, thereby exerting systemic metabolic effects and mitigating insulin resistance and hypertriglyceridemia. CREB3L3 is implicated as a therapeutic target for metabolic disorders, including hyperlipidemia, diabetes, atherosclerosis, and hepatocellular carcinoma.
Transcriptional activation or inhibition of downstream metabolic and inflammatory genes, including synergy with ATF6 and PPARα
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cyclic AMP-responsive element-binding protein 3-like protein 3 (CREB3L3).